However, men with higher PSA levels did show modest improvements in survival, suggesting that hormone therapy might be worthwhile for them. PSA (prostate-specific antigen) is produced by the prostate ...

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

Ultrahypofractionated radiotherapy yields non-inferior 10-year survival outcomes compared to conventional treatment in patients with intermediate- or high-risk localised prostate cancer.

Moderately hypofractionated radiotherapy, both isodose and dose-escalated, led to progression-free survival outcomes similar to that achieved with conventionally fractionated radiotherapy in patients ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The ...